BioNTech Valuation
| 22UA Stock | EUR 113.80 1.30 1.16% |
At this time, the firm appears to be overvalued. BioNTech SE shows a prevailing Real Value of €109.25 per share. The current price of the firm is €113.8. Our model approximates the value of BioNTech SE from analyzing the firm fundamentals such as Profit Margin of 0.56 %, current valuation of 29.68 B, and Return On Equity of 0.76 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BioNTech's price fluctuation is very steady at this time. Calculation of the real value of BioNTech SE is based on 3 months time horizon. Increasing BioNTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioNTech stock is determined by what a typical buyer is willing to pay for full or partial control of BioNTech SE. Since BioNTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioNTech Stock. However, BioNTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 113.8 | Real 109.25 | Hype 113.8 |
The real value of BioNTech Stock, also known as its intrinsic value, is the underlying worth of BioNTech SE Company, which is reflected in its stock price. It is based on BioNTech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioNTech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioNTech SE helps investors to forecast how BioNTech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioNTech more accurately as focusing exclusively on BioNTech's fundamentals will not take into account other important factors: BioNTech Total Value Analysis
BioNTech SE is presently anticipated to have takeover price of 29.68 B with market capitalization of 30.49 B, debt of 171.6 M, and cash on hands of 914.9 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BioNTech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.68 B | 30.49 B | 171.6 M | 914.9 M |
BioNTech Investor Information
About 64.0% of the company shares are owned by insiders or employees . The book value of BioNTech was presently reported as 76.45. The company has Price/Earnings To Growth (PEG) ratio of 0.04. BioNTech SE recorded earning per share (EPS) of 38.32. The entity last dividend was issued on the 2nd of June 2022. Based on the key indicators obtained from BioNTech's historical financial statements, BioNTech SE is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.BioNTech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioNTech has an asset utilization ratio of 119.87 percent. This implies that the Company is making €1.2 for each dollar of assets. An increasing asset utilization means that BioNTech SE is more efficient with each dollar of assets it utilizes for everyday operations.BioNTech Ownership Allocation
BioNTech holds a total of 242.68 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.0 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BioNTech Profitability Analysis
The company reported the revenue of 18.98 B. Net Income was 10.29 B with profit before overhead, payroll, taxes, and interest of 16.07 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioNTech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioNTech and how it compares across the competition.
About BioNTech Valuation
The stock valuation mechanism determines BioNTech's current worth on a weekly basis. Our valuation model uses a comparative analysis of BioNTech. We calculate exposure to BioNTech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioNTech's related companies.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people.
8 Steps to conduct BioNTech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioNTech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioNTech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioNTech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioNTech's revenue streams: Identify BioNTech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioNTech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioNTech's growth potential: Evaluate BioNTech's management, business model, and growth potential.
- Determine BioNTech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioNTech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |